The global biologics API market is estimated to grow from USD 68.4 billion in the current year to USD 145.9 billion by 2035, at a CAGR of 8.0% during the forecast period, till 2035.
Numerous major biopharmaceutical companies, including Novartis, Pfizer, Roche, and Eli Lilly, are backing the active pharmaceutical ingredient production within their in-house API manufacturing sites to efficiently produce a range of biologics. Additionally, substantial advancements are occurring in the biomanufacturing sector. Recently, Merck revealed plans for a 470,000-square-foot advanced biologics center of excellence in Wilmington, Delaware, aimed at the commercial manufacturing of innovative biologics and therapies, including powerful antibody-drug conjugates (ADCs).
With the advancement of biologics and their approval by regulatory bodies, it is anticipated that API production will increase, coupled with biologic developers manufacturing active pharmaceutical ingredients in their own facilities. Additionally, to satisfy the demand for biologics, the production of APIs will continue to be outsourced to contract manufacturers, creating a market opportunity for biologics API CDMO.
Biologics API Market: Growth and Trends
Biologics active pharmaceutical ingredients (API) refer to the biologically active substances in biological medications that are accountable for generating the intended therapeutic outcomes in patients. The therapeutic biologically active components are generated through a variety of biotechnological methods / techniques, including recombinant DNA technology. It is important to note that till date, over 400 biologics have been approved by the FDA, which includes monoclonal antibodies, mRNA therapies and vaccines, as well as bispecific antibodies. Significantly, the worldwide transition to personalized therapy has heightened interest and investment in the biologics API sector.Numerous major biopharmaceutical companies, including Novartis, Pfizer, Roche, and Eli Lilly, are backing the active pharmaceutical ingredient production within their in-house API manufacturing sites to efficiently produce a range of biologics. Additionally, substantial advancements are occurring in the biomanufacturing sector. Recently, Merck revealed plans for a 470,000-square-foot advanced biologics center of excellence in Wilmington, Delaware, aimed at the commercial manufacturing of innovative biologics and therapies, including powerful antibody-drug conjugates (ADCs).
With the advancement of biologics and their approval by regulatory bodies, it is anticipated that API production will increase, coupled with biologic developers manufacturing active pharmaceutical ingredients in their own facilities. Additionally, to satisfy the demand for biologics, the production of APIs will continue to be outsourced to contract manufacturers, creating a market opportunity for biologics API CDMO.
Growth Drivers: Strategic Enablers of Market Expansion
Market drivers in the biologics API market include rising prevalence of chronic diseases and accelerating demand for advanced biologics like cell / gene therapies, vaccines, bispecific antibodies, and ADCs.Market Challenges: Critical Barriers Impeding Progress
Stringent regulatory standards for quality, safety, and efficacy pose major hurdles, alongside high manufacturing costs and complex production processes. Supply chain disruptions, need for specialized high-containment facilities, and scaling difficulties for high-potency biologics add operational barriers. Intense competition and environmental sustainability concerns in API production also threaten profitability.Biologics API Market: Key Insights
The report delves into the current state of the biologics API market and identifies potential growth opportunities within industry. Some key findings from the report include:
- Presently, the biologics API market (by value) is anticipated to be USD 70 billion, with monoclonal antibodies capturing the majority market share by value.
- The market growth is indicative of the growing interest of stakeholders in the field of biologics active pharmaceutical ingredients; in fact, close to 50% of market is likely to be captured by North America.
- Given the rising prevalence of chronic diseases and the increasing demand for biologics, the biologics active pharmaceutical ingredients industry is well-positioned for future growth.
- Over 25 million liters is the current volume of other biologics API market. This demand is likely to reach more than 75 million liters by 2035 with monoclonal antibodies API capturing the majority (50.5%) market share.
Biologics API Market
The market sizing and opportunity analysis has been segmented across the following parameters:
By Type of Modality
- Monoclonal Antibodies
- Proteins / Peptides
- Vaccines
- Cell Therapies
- Biosimilars
- Bispecific Antibodies
- ADCs
- Gene Therapies
- mRNA Therapies and Vaccines
By Type of Expression System
- Mammalian
- Microbial
- Others
By Type of Bioreactor
- Single-use Bioreactors
- Stainless-steel Bioreactors
By Scale of Operation
- Preclinical / Clinical
- Commercial
By Type of Manufacturer
- In-house Manufacturers
- CMOs / CDMOs
- Hybrid Manufacturers
By Geographical Regions
- North America
- Europe
- Asia-Pacific
- Middle East and North Africa
- Latin America
Biologics API Market: Key Segments
Market Share by Type of Expression System: Mammalian Expression Systems are Likely to Drive the Demand
In terms of expression systems, the biologics API market is segmented across mammalian, microbial and other expression systems. The biologics API market analysis forecast suggests that the mammalian expression system category will dominate the market, securing over 75% of the overall revenue share. Moreover, the existing mammalian expression system constitutes 90%, 86%, and 77% of the overall ADC API market, cell and gene therapy API market. The other expression systems segment is anticipated to reach a greater CAGR. This results from the growing use of plant and insect cell lines to produce various biologics, including protein-peptide therapeutics.Market Share by Type of API Manufacturer: How Large is the API Manufacturer Segment?
According to the biologics API market forecast, currently, in-house segment holds the biggest share and is expected to remain stable moving forward. This arises from the proactive investment, growth, and acquisition efforts of the internal producers in this field. Certain biologics API producers with internal facilities are AbbVie, Amgen, Eli Lilly, and Sanofi. In the coming years, the hybrid manufacturing segment is expected to expand at a higher CAGR (8.3%) throughout the prediction period.North America: Remains the Center for Technological Innovations
At present, North America leads the market and is expected to continue this trend in the future. This expansion results from the presence of prominent pharmaceutical developers and manufacturers, advanced healthcare systems, and strong research and development (R&D) capabilities in the area, promoting ongoing advancement for tailored therapies. Moreover, the significant occurrence of chronic illnesses in this area has prompted the government to enhance efforts for creating novel treatments.Biologics API Market: Research Coverage
- Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the biologics API market, focusing on key market segments, including [A] type of modality, [B] type of expression system, [C] type of bioreactor, [D] scale of operation, [E] type of manufacturer, and [F] geographical regions.
- Market Landscape Analysis: A detailed overview of the current market landscape of biologics API manufacturers along with information on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of biologic, [E] type of API manufactured, [F] scale of operation, and [G] geographical presence.
- Company Competitiveness Analysis: An insightful company competitiveness analysis of prominent biologics API contract manufacturers in the biologics API manufacturing industry, based on several relevant parameters, such as [A] supplier strength, [A] service portfolio and [A] number of biologics offered.
- Company Profiles: In-depth profiles of prominent players North America, Europe and Asia-Pacific that are engaged in the peptide therapeutics manufacturing market based on [A] year of establishment, [B] location of headquarters, [C] product portfolio, [D] recent developments and [E] an informed future outlook.
- Market Impact Analysis: An in-depth analysis of the factors that can impact the growth of the global biologics API market. It also features identification and analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.
Key Questions Answered in this Report
- Which are the leading companies in the biologics API market?
- Which region dominates the biologics API market?
- What are the key trends observed in the biologics API market?
- What factors are likely to influence the evolution of this market?
- What are the primary challenges faced by biologic API developers?
- What is the current and future market size?
- What is the CAGR of this market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Reasons to Buy this Report
- The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
- The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
- The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
- The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
- The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
- The report allows for more effective communication with the audience and in building strong business relations.
Additional Benefits
- Complementary PPT Insights Pack
- Complimentary Excel Data Packs Covering All Analytical Modules
- Up to 15% Complimentary Content Customization
- In-Depth Report Walkthrough with the Research Team
- Complimentary Report Update if the Report is 6+ Months Old
Table of Contents
1. BACKGROUND
2. RESEARCH METHODOLOGY
3. MARKET DYNAMICS
4. MACRO-ECONOMIC INDICATORS
6. MARKET LANDSCAPE
7. COMPANY COMPETITIVENESS ANALYSIS
8. COMPANY PROFILES: BIOLOGICS API CONTRACT MANUFACTURERS
9. GLOBAL BIOLOGICS API MARKET (BY VALUE)
10. ADC API MARKET (BY VALUE)
11. GENE THERAPY API MARKET (BY VALUE)
12. MONOCLONAL ANTIBODY API MARKET (BY VALUE)
13. BIOSIMILAR API MARKET (BY VALUE)
14. VACCINE API MARKET (BY VALUE)
15. BISPECIFIC ANTIBODY API MARKET (BY VALUE)
16. mRNA THERAPEUTICS API MARKET (BY VALUE)
17. PROTEIN / PEPTIDE THERAPEUTICS API MARKET (BY VALUE)
18. CELL THERAPY API MARKET (BY VALUE)
19. GLOBAL BIOLOGICS API MARKET (BY VOLUME)
20. GENE THERAPY API MARKET (BY VOLUME)
21. CELL THERAPY API MARKET (BY VOLUME)
23. CONCLUDING REMARKS`
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Lonza Group
- Thermo Fisher Scientific (Patheon)
- FUJIFILM Biotechnologies
- AGC Biologics
- Boehringer Ingelheim
- Amgen
- AbbVie
- Pfizer CentreOne
- Syngene International
- Curia Global
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 209 |
| Published | June 2026 |
| Forecast Period | 2026 - 2035 |
| Estimated Market Value ( USD | $ 68.4 Billion |
| Forecasted Market Value ( USD | $ 145.9 Billion |
| Compound Annual Growth Rate | 8.0% |
| Regions Covered | Global |
